NZ769136A - Nlrp3 modulators - Google Patents
Nlrp3 modulatorsInfo
- Publication number
- NZ769136A NZ769136A NZ769136A NZ76913619A NZ769136A NZ 769136 A NZ769136 A NZ 769136A NZ 769136 A NZ769136 A NZ 769136A NZ 76913619 A NZ76913619 A NZ 76913619A NZ 769136 A NZ769136 A NZ 769136A
- Authority
- NZ
- New Zealand
- Prior art keywords
- nlrp3
- modulators
- nlrp3 modulators
- compounds
- iib
- Prior art date
Links
- 101150061038 NLRP3 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662240P | 2018-04-25 | 2018-04-25 | |
| US201862764818P | 2018-08-16 | 2018-08-16 | |
| US201962825044P | 2019-03-28 | 2019-03-28 | |
| PCT/US2019/028823 WO2019209896A1 (en) | 2018-04-25 | 2019-04-24 | Nlrp3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ769136A true NZ769136A (en) | 2024-04-26 |
Family
ID=66677224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ769136A NZ769136A (en) | 2018-04-25 | 2019-04-24 | Nlrp3 modulators |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12037344B2 (enExample) |
| EP (2) | EP3784670B1 (enExample) |
| JP (2) | JP7351850B2 (enExample) |
| KR (1) | KR102711180B1 (enExample) |
| CN (2) | CN112521387B (enExample) |
| AU (1) | AU2019261582A1 (enExample) |
| BR (1) | BR112020021539A2 (enExample) |
| CA (1) | CA3097865A1 (enExample) |
| CL (1) | CL2020002719A1 (enExample) |
| CO (2) | CO2021006672A2 (enExample) |
| ES (1) | ES2971122T3 (enExample) |
| IL (1) | IL278173A (enExample) |
| MX (1) | MX2020011234A (enExample) |
| NZ (1) | NZ769136A (enExample) |
| PE (1) | PE20210160A1 (enExample) |
| SG (1) | SG11202010463TA (enExample) |
| TW (1) | TW202014420A (enExample) |
| WO (1) | WO2019209896A1 (enExample) |
| ZA (1) | ZA202007307B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021142203A1 (en) * | 2020-01-10 | 2021-07-15 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
| CN121270550A (zh) * | 2020-04-16 | 2026-01-06 | 因赛特公司 | 稠合三环kras抑制剂 |
| WO2021219784A1 (en) | 2020-04-30 | 2021-11-04 | Janssen Pharmaceutica Nv | New triazinoindole compounds |
| WO2021231526A1 (en) | 2020-05-13 | 2021-11-18 | Incyte Corporation | Fused pyrimidine compounds as kras inhibitors |
| KR20230016658A (ko) * | 2020-05-28 | 2023-02-02 | 얀센 파마슈티카 엔.브이. | 화합물 |
| WO2022037631A1 (zh) * | 2020-08-21 | 2022-02-24 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和用途 |
| WO2022047093A1 (en) | 2020-08-28 | 2022-03-03 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of kras |
| WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
| EP3984535A1 (en) * | 2020-10-16 | 2022-04-20 | Albert-Ludwigs-Universität Freiburg | Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome |
| EP4251624B1 (en) * | 2020-11-24 | 2025-10-29 | Amgen Inc. | Tricyclic carboxamide derivatives as prmt5 inhibitors |
| CN114539095A (zh) * | 2020-11-26 | 2022-05-27 | 乐凯化学材料有限公司 | 3-（4-羟基-3-甲氧基-苯基）-2-氰基-2-丙烯酸乙酯的制备方法 |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| WO2023283213A1 (en) | 2021-07-07 | 2023-01-12 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| CA3224841A1 (en) | 2021-07-14 | 2023-01-19 | Zhenwu Li | Tricyclic compounds as inhibitors of kras |
| WO2023288039A1 (en) * | 2021-07-16 | 2023-01-19 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CA3229855A1 (en) | 2021-08-31 | 2023-03-09 | Incyte Corporation | Naphthyridine compounds as inhibitors of kras |
| US12030883B2 (en) | 2021-09-21 | 2024-07-09 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of KRAS |
| US12030884B2 (en) | 2021-10-01 | 2024-07-09 | Incyte Corporation | Pyrazoloquinoline KRAS inhibitors |
| KR20240101561A (ko) | 2021-10-14 | 2024-07-02 | 인사이트 코포레이션 | Kras의 저해제로서의 퀴놀린 화합물 |
| WO2025190317A1 (en) * | 2024-03-13 | 2025-09-18 | National Institute Of Biological Sciences, Beijing | Urea compounds as nlrp3 agonists |
| WO2026006603A1 (en) * | 2024-06-26 | 2026-01-02 | Wisconsin Alumni Research Foundation | Tlr7/tlr8 agonists for use in trifunctional radiopharmaceutical compounds |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110929A (en) * | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| AR046172A1 (es) | 2003-10-03 | 2005-11-30 | 3M Innovative Properties Co | Pirazolopiridinas y sus analogos; composiciones farmaceuticas que los contienen y su uso en la inhibicion de la biosintesis de citocinas |
| US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| US20090075980A1 (en) | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
| US20070259907A1 (en) | 2004-06-18 | 2007-11-08 | Prince Ryan B | Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines |
| US20080193468A1 (en) | 2004-09-08 | 2008-08-14 | Children's Medical Center Corporation | Method for Stimulating the Immune Response of Newborns |
| JP2008530252A (ja) | 2005-02-09 | 2008-08-07 | コーリー ファーマシューティカル グループ，インコーポレイテッド | オキシムおよびヒドロキシルアミンで置換されたチアゾロ［４，５−ｃ］環化合物ならびに方法 |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US20110294799A1 (en) | 2007-08-14 | 2011-12-01 | Novartis Ag | Organic Compounds |
| EP2303890A4 (en) | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| TWI557121B (zh) * | 2011-04-21 | 2016-11-11 | 原真股份有限公司 | 新穎激酶抑制劑 |
| SI2573073T1 (sl) | 2011-09-26 | 2015-02-27 | Sanofi | Pirazolokinolinonski derivati, njihova priprava in njihova terapevtska uporaba |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN104418867B (zh) * | 2013-08-26 | 2016-12-28 | 上海汇伦生命科技有限公司 | 作为PI3K/mTOR抑制剂的化合物，其制备方法和用途 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| US10654807B2 (en) | 2013-12-20 | 2020-05-19 | The University Of Kansas | Toll-like receptor 8 agonists |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| DK4001311T3 (da) | 2014-07-09 | 2026-02-02 | Birdie Biopharmaceuticals Inc | Anti-pd-l1/pd-1-kombinationer til behandling af tumorer |
| CN112546230A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| WO2016199943A1 (en) | 2015-06-11 | 2016-12-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗ｐｄ−１抗体及びその使用方法 |
| CN108289912A (zh) | 2015-09-01 | 2018-07-17 | 先天肿瘤免疫公司 | 具有提高的免疫力或免疫抑制性细胞因子抗性的免疫细胞及其用途 |
| CN105523955B (zh) | 2015-12-14 | 2018-08-17 | 北京嘉林药业股份有限公司 | 化合物及其在制备药物中的用途 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| EP3402255B1 (en) | 2016-02-02 | 2021-03-31 | Huawei Technologies Co., Ltd. | Emission power verification method, user equipment, and base station |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017184735A1 (en) | 2016-04-19 | 2017-10-26 | Ifm Therapeutics, Inc | Nlrp3 modulators |
| EP3445761A1 (en) | 2016-04-19 | 2019-02-27 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| ES3002968T3 (en) | 2017-07-14 | 2025-03-10 | Innate Tumor Immunity Inc | Nlrp3 modulators |
| JP7349450B2 (ja) | 2018-04-25 | 2023-09-22 | バイエル・アクチエンゲゼルシヤフト | 殺有害生物剤としての新規ヘテロアリール－トリアゾール化合物及びヘテロアリール－テトラゾール化合物 |
-
2019
- 2019-04-24 WO PCT/US2019/028823 patent/WO2019209896A1/en not_active Ceased
- 2019-04-24 US US17/049,612 patent/US12037344B2/en active Active
- 2019-04-24 AU AU2019261582A patent/AU2019261582A1/en not_active Abandoned
- 2019-04-24 CN CN202011468364.4A patent/CN112521387B/zh active Active
- 2019-04-24 SG SG11202010463TA patent/SG11202010463TA/en unknown
- 2019-04-24 PE PE2020001652A patent/PE20210160A1/es unknown
- 2019-04-24 ES ES19727780T patent/ES2971122T3/es active Active
- 2019-04-24 CN CN201980027881.7A patent/CN112074516A/zh active Pending
- 2019-04-24 KR KR1020207033384A patent/KR102711180B1/ko active Active
- 2019-04-24 JP JP2020559472A patent/JP7351850B2/ja active Active
- 2019-04-24 CA CA3097865A patent/CA3097865A1/en active Pending
- 2019-04-24 NZ NZ769136A patent/NZ769136A/en unknown
- 2019-04-24 EP EP19727780.9A patent/EP3784670B1/en active Active
- 2019-04-24 BR BR112020021539-2A patent/BR112020021539A2/pt not_active IP Right Cessation
- 2019-04-24 MX MX2020011234A patent/MX2020011234A/es unknown
- 2019-04-24 EP EP23211253.2A patent/EP4353235A3/en active Pending
- 2019-04-25 TW TW108114491A patent/TW202014420A/zh unknown
-
2020
- 2020-10-20 IL IL278173A patent/IL278173A/en unknown
- 2020-10-21 CO CONC2021/0006672A patent/CO2021006672A2/es unknown
- 2020-10-21 CL CL2020002719A patent/CL2020002719A1/es unknown
- 2020-10-21 CO CONC2020/0013155A patent/CO2020013155A2/es unknown
- 2020-11-24 ZA ZA2020/07307A patent/ZA202007307B/en unknown
-
2023
- 2023-09-14 JP JP2023149057A patent/JP7660634B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3097865A1 (en) | 2019-10-31 |
| KR20210005106A (ko) | 2021-01-13 |
| JP7351850B2 (ja) | 2023-09-27 |
| PE20210160A1 (es) | 2021-01-26 |
| BR112020021539A2 (pt) | 2021-01-19 |
| WO2019209896A1 (en) | 2019-10-31 |
| US20210267964A1 (en) | 2021-09-02 |
| CO2021006672A2 (es) | 2021-06-10 |
| EP4353235A2 (en) | 2024-04-17 |
| AU2019261582A1 (en) | 2020-11-12 |
| US12037344B2 (en) | 2024-07-16 |
| CN112074516A (zh) | 2020-12-11 |
| TW202014420A (zh) | 2020-04-16 |
| SG11202010463TA (en) | 2020-11-27 |
| JP2021522249A (ja) | 2021-08-30 |
| IL278173A (en) | 2020-11-30 |
| EP3784670A1 (en) | 2021-03-03 |
| ZA202007307B (en) | 2023-01-25 |
| EP4353235A3 (en) | 2024-07-31 |
| EP3784670B1 (en) | 2023-11-29 |
| JP2024001030A (ja) | 2024-01-09 |
| CN112521387B (zh) | 2023-08-22 |
| MX2020011234A (es) | 2020-11-11 |
| KR102711180B1 (ko) | 2024-09-26 |
| ES2971122T3 (es) | 2024-06-03 |
| CL2020002719A1 (es) | 2020-12-18 |
| CO2020013155A2 (es) | 2021-06-10 |
| CN112521387A (zh) | 2021-03-19 |
| JP7660634B2 (ja) | 2025-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011234A (es) | Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3). | |
| NZ761519A (en) | Nlrp3 modulators | |
| ZA201906832B (en) | Novel psma-binding agents and uses thereof | |
| ZA201906111B (en) | Cyclic di-nucleotides compounds for the treatment of cancer | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
| SA519410320B1 (ar) | مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل | |
| PH12019502646A1 (en) | Pyrazole magl inhibitors | |
| TN2019000211A1 (en) | Antitumoral compounds | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| WO2016100619A3 (en) | Treatment and diagnosis of cancer | |
| GEP20207160B (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| PH12019501690A1 (en) | Pyrimidine compound and pharmaceutical use thereof | |
| SA521422152B1 (ar) | Vanin مركبات عطرية غير متجانسة كمثبطات | |
| AU2016380190A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| NZ797702A (en) | Dual magl and faah inhibitors | |
| MX378739B (es) | Compuestos de 2-oxindol. | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX2021006490A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| JOP20200090A1 (ar) | عملية لتحضير بنزوثيوفين-2 يل بورونات | |
| PH12017501560A1 (en) | Tetrahydropyranyl benzamide derivatives | |
| WO2016187620A3 (en) | Anti-cancer compounds | |
| EA202092539A1 (ru) | Модуляторы nlrp3 | |
| EA202090283A1 (ru) | Модуляторы nlrp3 |